Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00734292 · ClinicalTrials.gov registry record · Phase 2
Single-dose Crossover Study to Evaluate the Early Bronchodilating Effect of FlutiForm HFA pMDI in Adult Subjects With Mild to Moderate Asthma
A Phase 2 study, sponsored by SkyePharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT00734292: Completed Phase 2 study, sponsored by SkyePharma.
NCT00734292 is a Phase 2 study that has completed, run by SkyePharma. The registered enrollment target is 39 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00734292, a Phase 2 study, has completed, sponsored by SkyePharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the early bronchodilating effect of SKP FlutiForm HFA pMDI compared to placebo.
Interventions
- DRUG fluticasone propionate, formoterol fumarate
- OTHER fluticasone propionate, formoterol fumarate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2008-09 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
What the finished NCT00734292 record still lists
NCT00734292 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower).
The record links to 0 conditions, and to 2 interventions - of which fluticasone propionate, formoterol fumarate is the first listed.
NCT00734292 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00734292 about?
NCT00734292 is a clinical study titled "Single-dose Crossover Study to Evaluate the Early Bronchodilating Effect of FlutiForm HFA pMDI in Adult Subjects With Mild to Moderate Asthma". The primary purpose of this study is to evaluate the early bronchodilating effect of SKP FlutiForm HFA pMDI compared to placebo.
What is the current status of trial NCT00734292?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2008-09. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00734292?
The interventions under investigation include: fluticasone propionate, formoterol fumarate (DRUG), fluticasone propionate, formoterol fumarate (OTHER).
Who is sponsoring clinical trial NCT00734292?
This trial is sponsored by SkyePharma, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00734292's enrollment target sits among peer trials
39 1459th of 2000 higher than 534 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia